Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Fourth quarter revenue was $10.89 billion, 5% lower versus the same quarter last year. Core organic revenue growth declined 4%. Fourth quarter GAAP diluted EPS was $4.20, 5% higher versus the same quarter last year, driven by 70 basis points.

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results

Beyond analysts' top -and-bottom-line estimates for Thermo Fisher (TMO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Thermo Fisher (TMO) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Thermo Fisher Scientific (TMO) closed at $553.39 in the latest trading session, marking a +0.3% move from the prior day.

Thermo Fisher Scientific (TMO) Laps the Stock Market: Here's Why

WALTHAM, Mass. & MONZA, Italy--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA) allowing the company to manufacture RNA-based products at its Monza, Italy site. The approval and associated certification support increased accessibility to novel therapies for patients with difficult to treat conditions, marking a significant achievement within the Thermo Fisher Scientifi.

Thermo Fisher Scientific Receives GMP approval from the Italian Medicines Agency (AIFA) for its Manufacturing facility of RNA-Based Products in Monza, Italy

In the latest trading session, Thermo Fisher Scientific (TMO) closed at $544.42, marking a +0.96% move from the previous day.

Thermo Fisher Scientific (TMO) Rises Higher Than Market: Key Facts

CARLSBAD, Calif.--(BUSINESS WIRE)--To optimize clinical manufacturing processes for innovators developing breakthrough cell therapies, Thermo Fisher Scientific today announced the launch of the Gibco™ Cell Therapy Systems (CTS™) Cellmation™ Software, a first-of-its-kind automation solution designed to connect and integrate workflows across multiple Thermo Fisher Scientific cell therapy instruments while enabling cGMP compliance. This new offering can help eliminate the need for costly custom so.

Thermo Fisher Scientific Unveils Industry's First Off-the-Shelf Validated Software Solution to Automate Cell Therapy Manufacturing Workflows

Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

Thermo Fisher Scientific reported $44.98 billion revenue in 2022 with a breakup of 29% for life science solutions and 47% for laboratory products and biopharma services among others. These revenue figures were 15% higher than the previous year, and almost a 50% rise in a five-year span. The company may be considered a blue chip one, but still shows a lot of signs of being a growth stock.

Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics

The latest trading day saw Thermo Fisher Scientific (TMO) settling at $544.32, representing a -0.31% change from its previous close.

Thermo Fisher Scientific (TMO) Stock Slides as Market Rises: Facts to Know Before You Trade

Thermo Fisher Scientific, Inc. (TMO) 42nd Annual J.P. Morgan Healthcare Conference Transcript

Thermo Fisher Scientific (TMO) reachead $531.23 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.

Thermo Fisher Scientific (TMO) Stock Drops Despite Market Gains: Important Facts to Note

Thermo Fisher Scientific has pledged to stop selling forensic technology and equipment in Tibet that could be used for identifying individuals, a spokesperson for the company said.

Thermo Fisher halts forensic tech sales in Tibet

Thermo Fisher Scientific (TMO) closed the most recent trading day at $537.36, moving +1.61% from the previous trading session.

Thermo Fisher Scientific (TMO) Advances While Market Declines: Some Information for Investors

Galapagos

Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (NYSE: TMO) (“Thermo Fisher”) for the decentralized manufacturing of Galapagos' point-of-care CAR-T product candidate in the San Francisco area.

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

CARLSBAD, Calif.--(BUSINESS WIRE)--Earlier this year, scientists unveiled the first draft of the pangenome, based on full genetic blueprints from 47 people around the world to create a more diverse representation of the human genome1. To more accurately account for this richer picture of human genomic variation, Thermo Fisher Scientific has launched the new Axiom™ PangenomiX Array*, its largest and most ethnically diverse array to date, offering optimal genetic coverage for population scale dis.

Thermo Fisher Scientific Launches PangenomiX Array to Support Population-Scale Disease Studies and Pharmacogenomics Research

In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.

Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leade.

Thermo Fisher Scientific to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2023 before the market opens on Wednesday, January 31, 2024, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 out.

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, January 31, 2024

Olink Holding AB

Quantum-Si has a ton of promise if the proteomics market continues to develop. Thermo Fisher indicated the future potential with its big pending acquisition of Olink.

Forget Quantum-Si Stock, Olink Acquirer Thermo Fisher Is a Better Long-Term Investment

Thermo Fisher (TMO) introduces the CorEvitas pharmacovigilance platform for clinical research registries.

Thermo Fisher (TMO) Unveils CorEvitas Pharmacovigilance Platform

Thermo Fisher's (TMO) PPD clinical research business is selected by BARDA to support the Phase II platform clinical trial to treat ARDS.

Thermo Fisher's (TMO) PPD Business Backs BARDA's Clinical Trial

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific's PPD clinical research business selected to implement first BARDA-supported Phase II platform clinical trial for ARDS.

Thermo Fisher Scientific's PPD Clinical Research Business Selected by BARDA to Support Phase II Platform Clinical Trial to Treat Acute Respiratory Distress Syndrome (ARDS)

Thermo Fisher Scientific (TMO) reachead $519.43 at the closing of the latest trading day, reflecting a -1.65% change compared to its last close.

Why Thermo Fisher Scientific (TMO) Dipped More Than Broader Market Today

Thermo Fisher (TMO) will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics.

Thermo Fisher (TMO) to Allocate IFA Testing Kits With New Pact

Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.

News for Thermo Fisher Scientific Stock (TMO)